Rezolute Inc

Change company Symbol lookup

Select an option...

RZLT Rezolute Inc

BAC Bank of America Corp

SDA SunCar Technology Group Inc

RAIN Rain Oncology Inc

EOI Eaton Vance Enhanced Equity Income Fund

OLNCF Omni Lite Industries Canada Inc

RGNX Regenxbio Inc

OGSYS Otis Gallery LLC

RDN Radian Group Inc

SLNO Soleno Therapeutics Inc

Go

Rezolute, Inc. (Rezolute) is a clinical-stage biopharmaceutical company, which is engaged in developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. The antibody modifies insulin’s binding and signaling to maintain glucose levels in a normal range, which counteracts the effects of elevated insulin in the body. It is a potential treatment for congenital hyperinsulinism (HI), which is an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase II. The Company is also developing RZ402, an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME) in Phase I.